Patients with pre-existing inflammatory bowel disease (IBD), including ulcerative colitis or Crohn's disease, should discuss their condition with their healthcare provider before starting semaglutide
Injectable tirzepatide, however, does exist
As Healio previously reported, in the STEP 1 study, published in The New England Journal of Medicine in February, adults with obesity assigned semaglutide 2.4 mg experienced substantial weight loss compared with placebo, with more than half of participants losing 15% of their body weight
10.1007/s11357-011-9212-x Age 19 Brown-BorgH
While the available data on the effects of treatment termination are insufficient, minimizing WR post-treatment is crucial to achieving sustained management of obesity in patients who have undergone bariatric surgery [65]
Sahay S, Khan E, Praveen A, Panthri M, Mirza Z, Gupta M